ES2181165T3 - Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas. - Google Patents

Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.

Info

Publication number
ES2181165T3
ES2181165T3 ES98903122T ES98903122T ES2181165T3 ES 2181165 T3 ES2181165 T3 ES 2181165T3 ES 98903122 T ES98903122 T ES 98903122T ES 98903122 T ES98903122 T ES 98903122T ES 2181165 T3 ES2181165 T3 ES 2181165T3
Authority
ES
Spain
Prior art keywords
wound healing
latency
preparation
medicinal product
peptide associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98903122T
Other languages
English (en)
Spanish (es)
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of ES2181165T3 publication Critical patent/ES2181165T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
ES98903122T 1997-02-13 1998-02-13 Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas. Expired - Lifetime ES2181165T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9702943.3A GB9702943D0 (en) 1997-02-13 1997-02-13 Wound healing

Publications (1)

Publication Number Publication Date
ES2181165T3 true ES2181165T3 (es) 2003-02-16

Family

ID=10807557

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98903122T Expired - Lifetime ES2181165T3 (es) 1997-02-13 1998-02-13 Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.

Country Status (12)

Country Link
US (1) US6319907B1 (https=)
EP (1) EP1009425B1 (https=)
JP (1) JP4307561B2 (https=)
AT (1) ATE223228T1 (https=)
AU (1) AU728851B2 (https=)
CA (1) CA2280873C (https=)
DE (1) DE69807710T2 (https=)
DK (1) DK1009425T3 (https=)
ES (1) ES2181165T3 (https=)
GB (1) GB9702943D0 (https=)
PT (1) PT1009425E (https=)
WO (1) WO1998035695A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756060B1 (en) * 1996-09-19 2004-06-29 Usbiomaterials Corp. Anti-inflammatory and antimicrobial uses for bioactive glass compositions
EP1296704A4 (en) * 2000-06-14 2005-04-27 Chanda Bhuwalka Zaveri PEPTIDES WITH PHYSIOLOGICAL ACTIVITY
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
CA2416788A1 (en) * 2000-07-31 2002-02-07 Tamar Tennenbaum Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds
WO2005016254A2 (en) * 2003-07-16 2005-02-24 The Ohio State University Research Foundation Methods and reagents for treating inflammation and fibrosis
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
EP2452686A3 (en) * 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2091557A2 (en) 2006-11-15 2009-08-26 Coda Therapeutics, INC. Improved methods and compositions for wound healing
CN102755649A (zh) * 2007-07-30 2012-10-31 希尔洛有限公司 药物组合物及相关方法
CA2701420C (en) * 2007-10-29 2016-02-09 Helix Biomedix Inc. Protective skin care tetrapeptides
AU2008343758A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
CA2710375A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
JP2011507599A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 改良医療デバイス
US20100172217A1 (en) * 2009-01-08 2010-07-08 Von Bezold Ernst System of Methods and Apparati for Handling and Modifying Information Energy and Matter by Formative Resonance
CA2751156A1 (en) * 2009-02-24 2010-09-02 Healor Ltd. Visfatin therapeutic agents for the treatment of acne and other conditions
EP2523677A2 (en) 2010-01-11 2012-11-21 Healor Ltd. Method for treatment of inflammatory disease and disorder
US9387183B2 (en) 2011-12-28 2016-07-12 Kuwait University Method of treating diabetes-related impaired wound healing
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
US10232009B1 (en) * 2017-09-29 2019-03-19 Pro Sunfun Biotech Research And Development Co., Ltd. Peptide for promoting wound healing, its composition and method of using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502036B1 (en) 1989-11-22 1995-12-20 Genentech, Inc. Latency associated peptide and uses therefor
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
WO1994009812A1 (en) 1992-10-26 1994-05-11 Kirin Brewery Company, Limited METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
US6074840A (en) * 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
WO1995026203A1 (en) * 1994-03-29 1995-10-05 The Victoria University Of Manchester Wound healing

Also Published As

Publication number Publication date
AU5995398A (en) 1998-09-08
WO1998035695A1 (en) 1998-08-20
CA2280873A1 (en) 1998-08-20
US6319907B1 (en) 2001-11-20
ATE223228T1 (de) 2002-09-15
HK1025504A1 (en) 2000-11-17
PT1009425E (pt) 2002-11-29
JP2001511797A (ja) 2001-08-14
GB9702943D0 (en) 1997-04-02
DE69807710D1 (de) 2002-10-10
EP1009425A1 (en) 2000-06-21
DE69807710T2 (de) 2003-06-05
EP1009425B1 (en) 2002-09-04
CA2280873C (en) 2010-04-06
DK1009425T3 (da) 2002-10-14
AU728851B2 (en) 2001-01-18
JP4307561B2 (ja) 2009-08-05

Similar Documents

Publication Publication Date Title
ES2181165T3 (es) Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
SV1995000045A (es) Benzoxazolil- y benzotiazoliloxazolidinonas, ref. le a 30616-sv
ES2194308T3 (es) Utilizacion de sustancias con una actividad de oxitocina en la preparacion de medicamentos para la curacion de heridas.
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
PT777482E (pt) Composicao de combinacao para utilizacao em doencas imunologicas
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
MX9202436A (es) Composiciones para el cuidado del cabello y metodo para su preparacion.
BR9100843A (pt) Inalador e embalagem de medicamento para aplicacao com o mesmo
ES2160712T3 (es) Nueva preparacion farmaceutica para tratamiento del dolor.
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
ES2159382T3 (es) Compuestos estilbenicos con grupo adamantilo, composiciones que los contienen y utilizaciones.
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
AR004510A1 (es) Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
SE9701161D0 (sv) New use I
BRPI0107493B8 (pt) substâncias para uso no tratamento de psoríase
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
ITRM910002A0 (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.